
US-based private investment firm Wellington Management Group LLP has decreased its share holding in Genmab to 4.9%, the Danish biotech firm reports in a Wednesday press release.
Earlier in July, the investment firm had actually increased its ownership share beyond 5% to a total of 5.02%.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app